Lexicon Pharmaceuticals, Inc.
LXRXLexicon Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and development of new drugs, particularly in the areas of metabolic, autoimmune, and other serious diseases. Founded in 1995 and headquartered in The Woodlands, Texas, the company utilizes its proprietary gene knockout technology to identify potential drug targets and develop innovative therapies.
Company News
A clinical study demonstrated sotagliflozin's potential benefits for heart failure patients with preserved ejection fraction (HFpEF) without diabetes, showing significant improvements in cardiac structure, function, and quality of life.
Lexicon Pharmaceuticals submitted additional clinical data to the FDA for Zynquista®, an oral SGLT1/SGLT2 inhibitor for type 1 diabetes, following a complete response letter in December 2024. The FDA requires more time to review the data and will provide feedback in Q4 2025.
Lexicon Pharmaceuticals will present patient survey data on diabetic peripheral neuropathic pain (DPNP) at the American Society of Pain and Neuroscience meeting, highlighting their investigational non-opioid treatment pilavapadin.
U.S. stock futures fell on Monday after three consecutive days of decline. Goldman Sachs has increased its U.S. recession probability from 20% to 35% and warned that the risk of further market correction is still looming.
Three small-cap stocks, Argan, Lightwave Logic, and Lexicon Pharmaceuticals, posted significant gains last week despite broader market uncertainty, with Lexicon surging 58% on a licensing deal with Novo Nordisk.
